BCL2 and colitis: Using the TNBS model, mesalamine treatment reduced colitis severity in mice in part through reducing BCL-2 colonic expression levels [80], which is in agreement with our finding using the DSS model where E121 also reduced its expression in the colon homogenate (Fig 5).